Mohamed-Bilal Fares, PhD, earned his doctorate in biotechnology and bioengineering from the Swiss Federal Institute of Technology in Lausanne (EPFL) in 2015. During his PhD studies, Dr. Fares led and contributed to several projects aimed at developing novel preclinical models of Parkinson’s disease (PD) and at understanding the effect of alpha-synuclein modifications and mutations on PD pathology. He undertook postdoctoral studies at EPFL, investigating mechanisms of protein spreading in Huntington’s disease, and at PMI Science, Switzerland, where he established novel stem cell-derived preclinical models of synucleinopathy for drug discovery. In 2019, Dr. Fares co-founded “ND Biosciences”, an EPFL-spinoff with the mission of accelerating the development of next-generation therapeutics and diagnostics for neurodegenerative diseases. In 2021, Dr. Fares earned his MBA from Quantic School of Business and Technology, USA, and he currently serves as director of research and development at ND Biosciences.